Manhattan submits obesity drug for approval in Switzerland, delays phase 2 psoriasis study

By Lisa Kerner

Erie, Pa., April 28 - Manhattan Pharmaceuticals, Inc. updated the status of two of its products in development - oral Oleoyl-estrone for obesity and topical PTH (1-34) for psoriasis.

The phase 2a protocol for Oleoyl-estrone has been submitted to SwissMedic, the Swiss medical regulatory authority, for review.

Manhattan said it plans to begin the trial immediately following final regulatory approval.

Separately, dosing of topical PTH (1-34) for psoriasis in a phase 2a study has been delayed due to formulation issues coupled with the difficulty of conducting a psoriasis study in the summer, since the disease naturally improves during that time.

In its published phase 1/2 study, Manhattan said more than 60% of patients experienced complete clearing of treated psoriasis lesions and 85% experienced at least partial clearing.

Manhattan is a development-stage pharmaceutical company located in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.